Brief Summary:
The main purpose of the study is to learn about how well Trumenba vaccine shot works against gonorrhea infection.
This study looks at data records from a database in the United States.
This study includes patient's data from the database who:
* Are 15-30 years old.
* Have received at least one dose of Trumenba and a MenACWY vaccine or who have received only MenACWY vaccine.
This data has already been collected in the past and is being studied between April and June of 2023.

Start Date24 Apr 2023

Sponsor / Collaborator

Pfizer Inc.

NCT04819113

/ CompletedPhase 3

A PHASE 3B, OPEN-LABEL, STUDY TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF NIMENRIX(Registered) IN HEALTHY INFANTS, GIVEN AT 3 AND 12 MONTHS OF AGE

This study will evaluate the safety and immunogenicity of a single dose of Nimenrix in infants at 3 months of age, followed by a second dose at 12 months of age. Current posology allows for 2 doses of Nimenrix before 6 months of age, where the first dose is administered from 6 weeks onwards with a second dose at least 2 months later, with a booster at 12 months; and in infants from 6 months of age, a single dose at 6 months, with a booster dose at 12 months. This study will provide valuable immunogenicity and safety data for a single dose in healthy infants <6 months of age, followed by the booster at 12 months

Start Date09 Apr 2021

Sponsor / Collaborator

Pfizer Inc.

NL-OMON20287

/ SuspendedNot ApplicableIIT

Primary and booster meningococcal vaccination in Dutch elderly: study to investigate the immune response and determine functional antibodies after the tetravalent MenACWY-TT conjugate vaccine in the elderly population’

Start Date01 Jan 2021

Sponsor / Collaborator

National Institute For Health & Welfare

100 Clinical Results associated with Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

100 Translational Medicine associated with Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

100 Patents (Medical) associated with Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

327

Literatures (Medical) associated with Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

01 Jan 2025·Vaccine

Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)

Article

Author: Huang, Vivian ; Toback, Seth ; Liu, Xinxue ; Beyhaghi, Hadi ; Rousculp, Matthew D ; Marchese, Anthony M ; Faust, Saul N

Reactogenicity, the occurrence of vaccine side effects, can impact vaccine acceptance. There is limited data comparing the reactogenicity of COVID-19 vaccines to other routinely used vaccines, such as the meningococcal conjugate vaccine (MenACWY). In a trial of UK adults, participants received a third COVID-19 vaccine dose (NVX-CoV2373, BNT162b2, or mRNA1273) alongside MenACWY as an active control. Compared to MenACWY, we found that mRNA vaccines, particularly mRNA1273, showed the greatest relative increase in side effects, while protein-based NVX-CoV2373 generally elicited similar reactogenicity to MenACWY. These findings suggest that platform type can influence vaccine reactogenicity, and further research is needed to compare COVID-19 vaccines with other routinely administered vaccines.

01 Jan 2025·Vaccine

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose

Article

Author: O'Neill, Robert ; Gruber, William C ; Maguire, Jason D ; Zolotas, Lefteris ; Anderson, Annaliesa S ; Gruber, William C. ; Anderson, Annaliesa S. ; Maguire, Jason D. ; Beeslaar, Johannes ; Jodar, Luis ; Maansson, Roger ; Moughan, Beth ; Peyrani, Paula ; Drazan, Daniel ; Peterson, James

BACKGROUNDVaccination against 5 prominent meningococcal serogroups (A/B/C/W/Y) is necessary for broad disease protection. We report immunopersistence through 4 years after a 2-dose (6-month interval) pentavalent MenABCWY primary vaccine series and safety and immunogenicity of a booster administered 4 years after primary vaccination.METHODSThis randomized, active-controlled, observer-blinded study was conducted in the United States and Europe. In stage 1, healthy MenACWY vaccine-naive or -experienced 10- to 25-year-olds were randomized 1:2 to receive MenABCWY and placebo or MenB-fHbp and MenACWY-CRM. Eligible participants were randomly selected to participate in stage 2, which was an open-label immunopersistence and booster extension. Immunogenicity was assessed through serum bactericidal antibody using human complement (hSBA) assays with serogroups A/C/W/Y (MenA/C/W/Y) and 4 primary serogroup B (MenB) test strains. Immunogenicity endpoints included hSBA seroprotection rates through 48 months after primary vaccination and 1 month after the booster. Safety endpoints included booster reactogenicity events and adverse events (AEs).RESULTSOf 1379 eligible participants, 353 entered stage 2; 242 completed the 48-month blood draw after primary vaccination and 240 completed the booster vaccination phase. MenA/C/W/Y seroprotection rates remained high for 4 years following a 2-dose MenABCWY primary series (MenACWY-naive, 62.0 %-100.0 %; MenACWY-experienced, 98.7 %-100.0 %) and trended higher than those after a single MenACWY-CRM dose (MenACWY-naive, 38.1 %-95.2 %; MenACWY-experienced, 89.7 %-100.0 %). Corresponding seroprotection rates against MenB remained stable and generally higher than baseline (MenABCWY, 18.2 %-36.6 %; MenB-fHbp, 16.2 %-31.9 % across strains). Following a booster, seroprotection rates against all 5 serogroups were ≥ 93.8 % across groups. Most booster dose reactogenicity events were mild or moderate in severity, and AEs were infrequent.CONCLUSIONSImmune responses remained high for MenA/C/W/Y and above baseline for MenB through 4 years after the MenABCWY primary series, with robust responses for all 5 serogroups observed following a booster. The MenABCWY booster had an acceptable safety and tolerability profile consistent with the primary series. NCT03135834.

01 Jan 2025·Vaccine

Impact on meningococcal disease of different vaccination strategies with 4CMenB and MenACWY-CRM197 in infants and adolescents in Argentina

Article

Author: Urueña, Analia ; Karwala, Piotr ; Nocita, Florencia ; Graña, Maria Gabriela ; Giglio, Norberto ; Pannunzio, Maria Eugenia ; Gómez, Jorge Alberto

BACKGROUNDInvasive meningococcal disease (IMD) is a life-threatening disease, primarily affecting infants and children. Argentina introduced routine meningococcal vaccination in infants and adolescents in 2017, with MenACWY vaccination targeting serogroups A, C, W, and Y (current National Immunization Program [cNIP]). Serogroup B, more prevalent since 2015, became predominant in children. The dynamic trends of IMD epidemiology and availability of a four-component meningococcal B vaccine (4CMenB) call for a reassessment of the best schedule to optimize IMD prevention. The objective was to model the public health impact of routine 4CMenB and/or MenACWY in infants and adolescents, using different vaccination strategies compared with the cNIP in Argentina.METHODSA published dynamic transmission model adapted for Argentina evaluated six vaccination strategies versus the cNIP: infant 4CMenB alone (1), infant 4CMenB with adolescent MenACWY (2), adolescent MenACWY alone (3), infant 4CMenB & MenACWY (4), infant MenACWY alone (5), and infant 4CMenB & MenACWY with adolescent MenACWY (6).RESULTSStrategies including adolescent MenACWY with infant 4CMenB (or 4CMenB plus MenACWY) vaccination had the largest impact on increasing IMD prevention i.e., up to 23 % higher than the cNIP after 25 years. Strategies including 4CMenB (1, 2, 4, 6) had the largest reduction of serogroup B IMD (impact is seen among children 0-4 years old) i.e., a 39 % decrease within the first five years of introducing 4CMenB. Strategies including adolescent MenACWY (cNIP, 2, 3 and 6) had the largest reduction of serogroup ACWY IMD, with near elimination after 30 years (impact seen in all ages, due to herd protection).CONCLUSIONSAdding routine infant 4CMenB (either to the complete cNIP or instead of infant MenACWY) could further reduce IMD cases, sequelae, and deaths in Argentina. In addition, maintaining the adolescent MenACWY program, with its herd immunity benefits, could achieve near elimination of serogroup ACWY IMD over 30 years.

News (Medical) associated with Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

08 Jan 2025

·www.prnewswire.com

Clarivate Identifies Eleven Potential Blockbuster and Transformative Drugs in Annual Drugs to Watch Report

Anticipated advancements in obesity, oncology, gene therapy and other areas poised to revolutionize patient care LONDON, Jan. 8, 2025 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to redefine the future of healthcare. This year, the highly anticipated resource highlights 11 drugs projected to achieve blockbuster status or revolutionize treatment paradigms within five years. Since its inception, Drugs to Watch has identified over 98 transformative therapies, cementing its role as an essential resource for navigating the ever-evolving pharmaceutical landscape. This year's report, powered by insights from the Clarivate Cortellis intelligence suite of products, highlights 11 therapies that have recently launched or are set to debut in 2025. These innovations, addressing critical challenges in areas such as obesity, oncology, and gene therapy, are forecast to achieve blockbuster sales by 2030 or dramatically improve patient outcomes on a global scale. The report also explores pivotal trends shaping the industry, including the surging demand for obesity treatments, the transformative potential of gene editing, and the growing impact of regulatory innovation. The report offers an in-depth analysis of the chronic disease market in Mainland China, spotlighting five therapies expected to exceed $1 billion in annual sales over the next five years or deliver transformative outcomes for patients. It also explores critical topics shaping global healthcare, including regulatory advancements, the role of radiopharmaceutical theranostics in oncology, and the growing use of real-world data (RWD) and patient-reported outcomes (PROs) to drive health equity and enhance regulatory submissions. Henry Levy, President, Life Sciences & Healthcare, Clarivate, remarked: "Innovation in the life sciences is reaching unprecedented heights, and this year's Drugs to Watch™ report once again demonstrates the industry's ability to deliver therapies that address unmet medical needs and challenge existing paradigms of care. At Clarivate, we take pride in the precision and reliability of our predictions—last year, we identified 13 molecules as Drugs to Watch, with 12 already approved and launched and one poised for launch. This track record reflects the strength of our comprehensive data and deep expertise. By continuing to provide actionable insights, we empower the sector to navigate opportunities, overcome challenges and drive progress in advancing global health." Mike Ward, Global Head of Thought Leadership, Life Sciences & Healthcare, Clarivate, stated: "2025 represents a turning point for the life sciences sector as it embraces cutting-edge technologies such as AI and machine learning to enhance drug discovery and development. This year's report captures the dynamic forces at play, including groundbreaking progress in precision oncology, the rise of radiopharmaceuticals, and the growing focus on addressing global health disparities." The 2025 Drugs to Watch™ report highlights key trends reshaping the life sciences landscape, emphasizing the transformative impact of emerging technologies and therapeutic breakthroughs. Advances in AI and machine learning are streamlining drug discovery, clinical trials, and real-world data integration, enabling precision medicine approaches. The obesity market is undergoing a revolution driven by next-generation GLP-1 therapies, while radiopharmaceutical theranostics are redefining cancer treatment with a "see it and treat it" paradigm. Gene editing technologies are unlocking new opportunities in personalized medicine, and evolving regulatory frameworks are fostering greater emphasis on patient-reported outcomes and health equity. Together, these trends showcase the sector's resilience and its ability to navigate challenges while driving innovation to improve patient care worldwide. This year's drugs to watch exemplify the fusion of innovation and dedication to advancing patient care in an increasingly complex healthcare ecosystem. The Drugs to Watch™ 2025 list include: AWIQLI® (LAI 287; insulin icodec) developed by Novo Nordisk | Type 1 and type 2 diabetes mellitus AWIQLI®, the first once-weekly, subcutaneous insulin, has launched in Australia, Canada, the EU, Mainland China, and Japan. Its weekly dosing offers a significant advantage over daily basal insulin, potentially reducing the treatment burden for patients with type 1 or type 2 diabetes (T1DM and T2DM). CagriSema (cagrilintide + semaglutide) developed by Novo Nordisk | Obesity and type 2 diabetes mellitus CagriSema, combining cagrilintide, a long-acting amylin analog, with semaglutide, promises superior efficacy over semaglutide (OZEMPIC/WEGOVY®) and tirzepatide (MOUNJARO/ZEPBOUND®) in treating obesity and type 2 diabetes. This next-generation GLP-1 therapy leverages the benefits of GLP-1s, such as enhanced insulin secretion and appetite reduction, while incorporating amylin's effects, including slowed glucose absorption and release. If approved, CagriSema will be the first fixed-dose combination of amylin and GLP-1 receptor agonists in the obesity and T2DM markets. COBENFY™ (KarXT; xanomeline-trospium) developed by Bristol Myers Squibb | Schizophrenia and psychosis related to Alzheimer's disease Amid setbacks for emerging schizophrenia treatments, the approval of COBENFY marks a transformative milestone as the first drug in over 30 years with a novel mechanism of action for treating schizophrenia. Combining xanomeline and trospium, COBENFY selectively targets M1 and M4 receptors, rather than traditional dopamine pathways, while minimizing cholinergic side effects. While further data is needed to assess its effectiveness in Alzheimer's disease-related psychosis, COBENFY shows strong commercial potential if proven effective in treating AD-related hallucinations and delusions. EBGLYSS™ (lebrikizumab) developed by Eli Lilly and Co and Almirall | Atopic dermatitis EBGLYSS™, the third biologic targeting IL-13 for atopic dermatitis, follows DUPIXENT® (dupilumab) and ADBRY®/ADTRALZA® (tralokinumab) to market. Its less frequent dosing, more selective IL-13 inhibition, and strong efficacy and safety data position it as a likely first-line treatment for moderate-to-severe atopic dermatitis when topical corticosteroids are inadequate. Fitusiran developed by Alnylam® Pharmaceuticals Inc and Sanofi | Hemophilia A and B Fitusiran, shown to be effective in phase 3 trials for both hemophilia A and B, regardless of inhibitor status, has the potential to offer a new approach to hemophilia treatment. This small interfering RNA (siRNA) therapy works by inhibiting SerpinPC1 mRNA, reducing antithrombin levels, promoting thrombin generation, and helping to rebalance hemostasis to prevent bleeds. Leveraging Alnylam® Pharmaceuticals' ESC-GalNAc conjugate technology, fitusiran could become the first antithrombin-lowering therapy based on a double-stranded RNA molecule, pending approval. GSK-3536819 (MenABCWY) developed by GSK plc | Meningococcus GSK plc's GSK-3536819 vaccine candidate, a 5-in-1, first-generation formulation, targets the five groups of Neisseria meningitidis (A, B, C, W, and Y) responsible for most invasive meningococcal disease (IMD) cases worldwide. It combines the antigenic components of GSK's licensed meningococcal vaccines, BEXSERO (MenB) and MENVEO (MenACWY), both of which have established efficacy and safety profiles. IMDELLTRA™ (tarlatamab-dlle) developed by Amgen | Small-cell lung cancer (SCLC) IMDELLTRA™ is a first-in-class immunotherapy for extensive-stage small cell lung cancer (ES-SCLC). Using Amgen's bispecific T cell engager (BiTE®) molecules, it targets CD3 on T cells and DLL3 on tumor cells, enabling T cells to attack and lyse the tumor. DLL3 is expressed on the surface of SCLC cells in more than 85% of patients but is minimally expressed on healthy cells making it an attractive target. This mechanism positions IMDELLTRA as a potential standard of care for previously treated ES-SCLC. mRESVIA (mRNA-1345) developed by Moderna Inc | RSV With its U.S. FDA approval in May 2024, mRESVIA® joined AREXVY and ABRYSVO, both featured in Drugs to Watch 2024, as respiratory syncytial virus (RSV) vaccines currently available for adults ages 60 years and older, helping further support the public health initiative to reduce the RSV-related disease burden. Even with available vaccines, RSV infections continue to be a public health concern, particularly for infants and older adults (65 years and older). SEL-212 developed by Sobi® and Cartesian Therapeutics Inc/Selecta Biosciences Inc | Gout SEL-212 is a novel, once-monthly treatment combining pegylated uricase (pegadricase; SEL-037) with ImmTOR™, an immune tolerance technology designed to inhibit the formation of anti-drug antibodies (ADAs). For this application, ImmTOR consists of SEL-110.36, an inhibitor of uricase-specific ADA. This approach may help overcome the limitations of reduced efficacy and tolerability seen with other biologic treatments, such as KRYSTEXXA® (pegloticase), in patients with chronic gout. Vepdegestrant (ARV-471) developed by Arvinas Inc and Pfizer Inc | Breast cancer A global collaboration between Arvinas Inc and Pfizer Inc, vepdegestrant may become the first PROteolysis Targeting Chimera (PROTAC®) protein degrader on the market. Designed to target and degrade the estrogen receptor (ER) protein, early studies suggest PROTAC-induced degradation is more complete than with oral selective estrogen receptor degraders (SERDs). This offers potential for overcoming endocrine resistance in breast cancer. Label expansions, including combination with IBRANCE® (palbociclib), are being explored. Zanzalintinib (XL092) developed by Exelixis Inc | Colorectal cancer, renal cell carcinoma and squamous cell carcinoma of head and neck Zanzalintinib is a third-generation oral tyrosine kinase inhibitor targeting VEGF receptors, MET, and TAM kinases involved in tumor growth and immunosuppression. Currently in phase 3 trials for non-clear-cell renal cell carcinoma (nccRCC), colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (SCCHN), the company anticipates one potential zanzalintinib launch per year starting as early as 2026. Compared to CABOMETYX® (cabozantinib), zanzalintinib may offer benefits, including approval for nccRCC histology and a broader patient population. Access the Drugs to Watch 2025 report from Clarivate, here. For more Drugs to Watch updates and analyses throughout the year, visit the Drugs to Watch web page and follow Clarivate for Life Sciences & Healthcare on LinkedIn and X. Join the conversation, using #DrugstoWatch. To learn more about how Clarivate can help healthcare companies inform and shape the drug discovery, development and delivery process, visit here. Methodology for the Clarivate Drugs to Watch 2025 Report To identify this year's Drugs to Watch, Clarivate drew from the expertise of over 160 analysts covering hundreds of diseases, drugs and markets, along with 11 integrated data sets that span the R&D and commercialization lifecycle, including: Cortellis Competitive Intelligence™, Disease Landscape & Forecast, Epidemiology Intelligence, BioWorld™, Cortellis Regulatory Intelligence™, Drug Timeline & Success Rates, Cortellis Clinical Trials Intelligence™, Cortellis Deals Intelligence™, Access & Reimbursement payer studies, Clarivate Real-World Data and Analytics, Web of Science™, Derwent Innovation™, and other industry sources including biopharma company press releases, filings and peer-reviewed publications. Candidate drugs in phase 2 or phase 3 trials, at pre-registration or registration stage, or already launched in 2024 were selected for analysis, including both novel treatments and already-marketed drugs pursuing new indications that could be particularly impactful. Drugs launched prior to 2024 were excluded. The dataset was filtered for drugs that had total forecast sales of $1 billion or more by 2030. Clarivate experts and analysts evaluated each drug in its individual context, based on factors such as expected approval or launch dates, competitive landscape, regulatory status, trial results, market dynamics and other key factors, and added novel drugs that, while likely to fall short of blockbuster status, are poised to be therapeutic game-changers. Please note that Clarivate analysts generated the data shown in this report prior to December 31, 2024. The Drugs to Watch 2025 Report and the treatments referenced in this release are based on Clarivate's current expectations per existing data, but actual results derived from the drugs named in the report and here may differ significantly. Clarivate is committed to comprehensively supporting customers across the entire drug, device and medical technology lifecycles to advance human health. By combining patient journey data, therapeutic area expertise, artificial intelligence and analytics in ways that unlock hidden insights, data-driven decisions and accelerating innovation, Clarivate's end-to-end research intelligence is designed to enable customers to make informed evidence-based decisions. About Clarivate Clarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit . Media Contact: Catherine Daniel Director, External Communications, Life Sciences & Healthcare [email protected] SOURCE Clarivate Plc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccinePhase 3Immunotherapy

10 Dec 2024

·www.pharmaceutical-technology.com

FDA to review GSK’s Nucala for COPD

GSK’s submission is supported by data from the MATINEE study, which assessed the safety and efficacy of the therapy. Credit: Magda Wygralak/Shutterstock. The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala (mepolizumab) as an add-on maintenance treatment for chronic obstructive pulmonary disease (COPD) in individuals with an eosinophilic phenotype. GSK’s submission is supported by data from the MATINEE study, which assessed the therapy’s safety and efficacy. The study involved 804 COPD patients exhibiting type 2 inflammation, as indicated by blood eosinophil count. The study’s diverse patient group included subjects with clinical presentations including emphysema, chronic bronchitis, or a combination of both. MATINEE achieved its primary endpoint, showing that adding mepolizumab to inhaled maintenance therapy significantly reduced the annualised rate of moderate/severe exacerbations compared to placebo, with subjects treated for 52 to 104 weeks. The outcomes are expected to form the basis of regulatory submissions worldwide. Nucala is already approved in the US for four IL-5-mediated conditions, including severe asthma and chronic rhinosinusitis with nasal polyps, but is not currently indicated for COPD treatment anywhere globally. COPD is a global health issue, affecting more than 390 million people, and more than 14 million in the US. Type 2 inflammation is observed in numerous immuno-inflammatory disorders and serves as the fundamental pathology that contributes to symptoms and exacerbations in up to 40% of individuals with COPD. Inflammation is generally identified by measuring blood eosinophil levels, a specific biomarker that can be evaluated through a blood test. This assessment can provide insights into a COPD patient’s likelihood of experiencing exacerbations and worsening of their condition and guide the development of treatment plans. The Prescription Drug User Fee Act (PDUFA) date for the potential new indication is 7 May 2025. In November 2024, the European Commission approved a single-vial, fully liquid presentation of the company’s Menveo vaccine (MenACWY), aimed at protecting against invasive meningococcal disease (IMD) caused by bacterial serogroups A, C, W and Y.

VaccineClinical ResultDrug ApprovalEmergency Use AuthorizationClinical Study

06 Dec 2024

·www.pharmaceutical-technology.com

Muna-GSK alliance to fast-track Alzheimer’s disease treatments

The partnership aims to fast-track Alzheimer’s disease treatments. Credit: wavebreakmedia/Shutterstock. Muna Therapeutics has entered a research alliance with GSK to expedite Alzheimer’s disease treatments by discovering and validating new drug targets. The partnership is set to leverage Muna’s MiND-MAP platform’s spatial transcriptomics to analyse brain samples from groups including Alzheimer’s patients and cognitively resilient individuals. It also utilises Muna’s expertise in mapping the response of the brain to pathological protein aggregates. Muna will receive €33.5m ($35.2m) in an upfront payment from GSK, which also includes potential milestone payments of €140m ($147.1m) per target, plus tiered royalties on the net sales of any resulting products. By examining postmortem human brain samples, the companies will identify potential new drug targets, which will be validated using Muna’s humanised cell and animal models suite with additional insights provided by patient tissue and biofluid samples. Muna will be responsible for leading the target identification and validation, while GSK will take the reins on drug development, overseeing preclinical activities, clinical development, manufacturing and commercialisation. Muna Therapeutics CEO Rita Balice-Gordon stated: “Our agreement marks a pivotal moment in Muna’s evolution and in the broader Alzheimer’s research landscape. “By combining GSK’s commitment to breakthrough science with our MiND-MAP platform’s ability to deliver novel insights into brain resilience, we aim to transform the landscape of drug discovery for neurodegenerative diseases and bring new hope to millions of patients worldwide.” The MiND-MAP platform offers a dataset of breadth and resolution, which is expected to drive the discovery and development of new therapies for Alzheimer’s. This dataset will be expanded and enhanced as part of the alliance. GSK respiratory/immunology research and development global head and SVP Kaivan Khavandi stated: “By applying spatial multi-omics to unique patient phenotypes, Muna’s MiND-MAP platform can determine the genetic and cellular basis of progression and resilience in neurodegenerative diseases.” In November 2024, the European Commission approved GSK’s single-vial, fully liquid Menveo vaccine (MenACWY) .

VaccineLicense out/inmRNAClinical Study

100 Deals associated with Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

External Link

KEGG	Wiki	ATC	Drug Bank
-	Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)	J07AH08	-

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Meningococcal Infections	NO	Pfizer Europe MA EEIG	20 Apr 2012
Meningococcal Infections	EU	Pfizer Europe MA EEIG	20 Apr 2012
Meningococcal Infections	IS	Pfizer Europe MA EEIG	20 Apr 2012
Meningococcal Infections	LI	Pfizer Europe MA EEIG	20 Apr 2012

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diphtheria	Phase 1	PH	GSK Plc	16 Jun 2005
Diphtheria	Phase 1	TH	GSK Plc	16 Jun 2005
Haemophilus Infections	Phase 1	PH	GSK Plc	16 Jun 2005
Haemophilus Infections	Phase 1	TH	GSK Plc	16 Jun 2005
Hepatitis B	Phase 1	PH	GSK Plc	16 Jun 2005
Hepatitis B	Phase 1	TH	GSK Plc	16 Jun 2005
Meningococcal Infections	Phase 1	TH	GSK Plc	16 Jun 2005
Meningococcal Infections	Phase 1	PH	GSK Plc	16 Jun 2005
Tetanus	Discovery	TH	GSK Plc	16 Jun 2005
Tetanus	Discovery	PH	GSK Plc	16 Jun 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04819113 (CTgov)	Phase 3	Meningococcal Infections	149	Nimenrix	venubcuqei(nuwjcfhray) = lrmnzigsvl cajfkdpitx (gjgykgamik, bgdvitvzms - gjkqslhmtw) View more	-	18 Mar 2024
NCT01939158 (CTgov)	Phase 3	Meningococcal Infections	803	Meningococcal vaccine GSK134612 (ACWY1d Group)	ryzeoyfkqs(tzosgsnuyh) = hglqqzvmoj kijarpniny (ruwwwpjaab, rpmigqhtzl - cgtjxuauet) View more	-	05 Oct 2021
				Meningococcal vaccine GSK134612 (ACWY2d Group)	ryzeoyfkqs(tzosgsnuyh) = lcqgwukpkm kijarpniny (ruwwwpjaab, psulnknguw - eayxjwplyg) View more
NCT03189745 (CTgov)	Phase 3	Meningococcal Infections	229	MenACWY-TT vaccine (ACWY-TT Group)	qacdaxtixm(vxeczfijxf) = mwrddsctzi mtfkwktfdg (jtorjzfsrs, woibbmjquz - rnfvbvnxym) View more	-	12 Oct 2020
				MencevaxACWY vaccine+MenACWY-TT vaccine (MenPS Group)	qacdaxtixm(vxeczfijxf) = zdoonkxzol mtfkwktfdg (jtorjzfsrs, jmigvjeiay - iciyigosra) View more
NCT01934140 (CTgov)	Phase 3	Meningococcal Infections	311	Meningococcal vaccine GSK134612 (ACWY-TT Group)	wzwqwxcxjj(cdsdulmpzx) = pqkimveorn krvcriadjw (gdlhqkxlaq, jogxalxpbu - wncphrvvnl) View more	-	28 Aug 2019
				Meningococcal vaccine GSK134612 (MenPS Group)	wzwqwxcxjj(cdsdulmpzx) = beswrufkxd krvcriadjw (gdlhqkxlaq, rxzejsmffp - lzdnnpadtv) View more
NCT01340898 (CTgov)	Phase 3	Meningococcal Infections	753	SynflorixTM+Meningococcal vaccine GSK 134612+Infanrix-IPV/HiberixTM (Nimenrix 3+1 Group)	kzyabhqgdo(tcfuqqxazg) = ykmxvmyawl izgidnaozk (ffkdibzvhz, qxtlrennme - enzeipbxcx) View more	-	06 Aug 2019
				SynflorixTM+Meningococcal vaccine GSK 134612+Infanrix-IPV/HiberixTM (Nimenrix 1+1 Group)	muopmxyzlm(osiztvcugq) = oxvonktaft penynjeqtj (aofmclwxte, hzcyzuzmnz - hpxynjzcch) View more
NCT01144663 (CTgov)	Phase 3	Meningococcal Infections	2,095	Synflorix™+Nimenrix™+Infanrix™ hexa (Nimenrix 3 Group)	rmqkbewfmu(oaqixjvybu) = zqhdfdcmwf cqeazaovzv (cijbdirlba, uezpgiaftu - xkyozffukq) View more	-	01 Feb 2019
				Synflorix™+Nimenrix™+Infanrix™ hexa (Nimenrix 2 Group)	rmqkbewfmu(oaqixjvybu) = xshizkdiia cqeazaovzv (cijbdirlba, eczqrmodnw - blnlleygre) View more
NCT01266993 (CTgov)	Phase 3	Meningococcal Infections	271	Nimenrix (GSK134612 vaccine) (Nimenrix Group)	ipainstfcf(bfahlaorks) = fiwrtyjnah uealfqozio (fkbzvrgced, wjptrrqfic - ewhdratyis) View more	-	31 Jan 2019
				Menjugate (Menjugate Group)	ipainstfcf(bfahlaorks) = duixdncird uealfqozio (fkbzvrgced, aiqfhtmvju - bziwrdjade) View more
NCT01777308 (CTgov)	Phase 3	Meningococcal Infections	156	Meningococcal conjugate vaccine GSK134612 (Menitorix Group)	rnkgdmqdlu(fzgmmstetf) = wjgtflnydv pfahhftjxr (ukmvitwoxy, zjhyrqdrfb - ihizttiulv) View more	-	25 Jan 2019
				Meningococcal conjugate vaccine GSK134612 (Meningitec + Hiberix Group)	rnkgdmqdlu(fzgmmstetf) = zxysyppvhv pfahhftjxr (ukmvitwoxy, efyzgghrpw - npcawosjev) View more
NCT00508261 (CTgov)	Phase 3	Meningococcal Infections	793	Nimenrix+Infanrix-hexa (Nimenrix + Infanrix-hexa Group)	ufixldyjjd(gcdkiwpttt) = gccbgxrtug grtqrpupir (kzsgmdihgf, zezpjtjnnx - jktpeivhtc) View more	-	24 Jan 2019
				Infanrix-hexa™ vaccine+Nimenrix™ vaccine (Nimenrix Group)	ufixldyjjd(gcdkiwpttt) = nzshlernch grtqrpupir (kzsgmdihgf, psraeemlrl - tqdtswcaqq) View more
NCT00661557 (CTgov)	Phase 2	Meningococcal Infections	271	Meningococcal vaccine GSK134612 (Nimenrix) (Mencevax Primed Group)	tvwaalozof(sskfgsxswv) = geuwaoaevn spofievbnd (zpttsdscus, cswrmztybm - sjvesumcga) View more	-	28 Dec 2018
				Meningococcal vaccine GSK134612 (Nimenrix) (Mencevax Naive Group)	tvwaalozof(sskfgsxswv) = dsprxoitde spofievbnd (zpttsdscus, mtnioaukil - votgicdnal) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Meningococcal group A, C, W 135 and Y conjugate vaccine(GlaxoSmithKline Plc)

Overview

Basic Info

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation